Social Survey Research Information Co., Ltd.

Dec 7th, 2017  -  Social Survey Research Information Co., Ltd.

Launch of PatientsMap 2017 JP

2017 version includes pharmaceutical manufacturer's e-detailing data

 

Launch of PatientsMap 2017 JP

2017 version includes pharmaceutical manufacturer's e-detailing data

December 7th, 2017

Social Survey Research Information Co., Ltd.

On September 29th, 2017, SSRI and M3 launched the PatientsMap Japan 2017 version.

PatientsMap is a database product which uncovers the types of diseases that various specialists see, and the monthly number of those patients. The data is collected from over 20,000 physicians covering approximately 400 diseases/conditions, and is utilized by over 50 companies in Japan.

In addition to the new PatientsMap Japan 2017 data, US data (2016 with n=5,000) and UK data (2015 with n=1,000) are also available.

<< Characteristics of PatientsMap Japan 2017 version>>

  1. Able to understand the e-detailing (provision of information via internet) situation

Manufacturers' e-detailing data is a new item in the PatientsMap 2017 version. Since PatientsMap is a database with over 20,000 physicians, it allows you to understand which manufacturers have high e-detailing rates from various aspects, such as specialty and regions.

 
  1. Able to understand the physicians' level of trust (confidence) in various manufacturers

In the 2016 version, PatientsMap added a question (data) on the "level of trust (confidence) in pharmaceutical manufacturers". This question is also asked in the 2017 version.

 
  1. Uncovers the number of patients who were prescribed drugs

In addition to the "number of patients seen", from 2015 version, PatientsMap added a question (data) on the "number of patients who were prescribed drugs". This question is also asked in the 2017 version.

 

 

You can access the demo page here:

https://research.ssri.co.jp/pmap/?--lang=en

Outline of PatientsMap Japan 2017:

The study was conducted in collaboration M3 by using their portal site "m3.com" registered physicians of over 250,000. Respondents were sampled randomly per each specialty.
Targeted disease401 conditions/diseases
Study targetM3.com registered physicians
Inclusion criteriaPhysicians working in hospitals and offices
MethodologyOnline survey
Sample size20,135
FieldworkApril 19 ~ August 6th, 2017
Study contents-        Diseases/conditions that they see
-        Number of patients that they see (per each disease)
-        Number of patients prescribed with drugs (per each disease)
-        Diseases in which they desire new drugs
-        Sales rep visitation
-        Level of trust/confidence in manufacturers
-        Received e-detailing
PatientsMap database can be purchased through either SSRI or M3
 
Contact Information (Social Survey Research Information Co., Ltd)
Chiharu Sakai (csakai@ssri.com)
Hitoshi Dennoh (hdennoh@ssri.com)
Tel: +81-3-3370-3474
 
Social Survey Research Information Co., Ltd
EstablishedApril 1982
Capital27 million JPY
President & CEOTakashi Makita
Number of staffs137
AddressHQ (Tokyo)
5-1-14 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023
Osaka office
4-6-3 Hirano-Cho, Chuo-ku, Osaka 541-0046
Affiliate companiesPD Research, SSRI CHINA
URLhttp://www.ssri.com/
M3 Inc.
EstablishedSeptember 2000
Capital15.3 billion JPY
Representative DirectorItaru Tanimura
Number of staffs4,370
Address1-11-44 Akasaka, Minato-ku, Tokyo 107-0052
URLhttp://corporate.m3.com/